| Validation of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: slight improvement over the 1987 ACR criteria. | |
MedLine Citation:
|
PMID: 21586440 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Recently, an American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) collaboration developed new classification criteria for rheumatoid arthritis (RA). OBJECTIVE: To evaluate the diagnostic and discriminative ability of these new criteria compared with the 1987 ACR criteria and the Visser decision rule. METHODS: 455 patients with early arthritis were studied. The diagnostic performance of the criteria was evaluated using methotrexate treatment within 1 year, expert opinion RA and erosive disease as 'gold standards'. Erosive disease was defined as a 0-3 year change in radiographic score of ≥5. RESULTS: The discriminative ability of the three criteria sets (2010 ACR/EULAR, 1987 ACR criteria and Visser algorithm) was similar with areas under the curve of 0.71-0.78 ('gold standard' methotrexate), 0.74-0.80 (gold standard expert opinion RA) and 0.63-0.67 (gold standard erosive disease after 3 years). The sensitivity of the 2010 ACR/EULAR criteria was highest with 0.85 (gold standard methotrexate). 86% of patients with RA and 51% of 'non-RA' patients according to the new criteria used methotrexate. CONCLUSION: The 2010 ACR/EULAR criteria were slightly more sensitive, but otherwise performed similarly to the older criteria. A high percentage of 'non-RA' patients used methotrexate, the gold standard for RA. The ability of the new criteria to identify patients with erosive disease was low, possibly owing to the effect of intensive treatment. |
Authors:
|
Karin Britsemmer; Jennie Ursum; Martijn Gerritsen; L H van Tuyl; Lilian van Tuyl; Dirkjan van Schaardenburg |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies Date: 2011-05-17 |
Journal Detail:
|
Title: Annals of the rheumatic diseases Volume: 70 ISSN: 1468-2060 ISO Abbreviation: Ann. Rheum. Dis. Publication Date: 2011 Aug |
Date Detail:
|
Created Date: 2011-06-30 Completed Date: 2011-11-18 Revised Date: 2011-12-09 |
Medline Journal Info:
|
Nlm Unique ID: 0372355 Medline TA: Ann Rheum Dis Country: England |
Other Details:
|
Languages: eng Pagination: 1468-70 Citation Subset: IM |
Affiliation:
|
Department of Rheumatology, Jan van Breemen Research Institute I Reade, Amsterdam, The Netherlands. k.britsemmer@reade.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Antirheumatic Agents / therapeutic use Arthritis, Rheumatoid / drug therapy, radiography* Disease Progression Early Diagnosis Female Follow-Up Studies Humans Male Methotrexate / therapeutic use Middle Aged Prognosis Severity of Illness Index* Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Antirheumatic Agents; 59-05-2/Methotrexate |
| Comments/Corrections | |
Erratum In:
|
Ann Rheum Dis. 2011 Nov;70(11):2060 Note: van Tuyl, Lilian [corrected to van Tuyl, L H] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The comparative risk of serious infections among rheumatoid arthritis patients starting or switching...
Next Document: Arthritogenicity of annexin VII revealed by phosphoproteomics of rheumatoid synoviocytes.